Gilead Sciences Stock EBITDA

GILD Stock

USD 66.91 0.12 0.18%

Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.

		Last Reported	Projected for Next Year
	EBITDA	7.6 B	4.9 B

As of April 24, 2024, EBITDA is expected to decline to about 4.9 B.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Gilead Sciences Company EBITDA Analysis

Gilead Sciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Gilead Sciences EBITDA

7.61 B

Most of Gilead Sciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Gilead EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Gilead Sciences is extremely important. It helps to project a fair market value of Gilead Stock properly, considering its historical fundamentals such as EBITDA. Since Gilead Sciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gilead Sciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gilead Sciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Long Term Debt	Capital Stock	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Intangible Assets	Short Long Term Debt	Net Invested Capital	Net Working Capital
Total Assets		0.95	0.7	0.93	-0.05	0.99	0.61	0.62	0.73	0.47	0.91	0.24	0.24	0.87	-0.77	-0.51	0.82	0.69	0.96	-0.25	0.69	0.21	0.73	0.24	-0.58	-0.48
Total Stockholder Equity	0.95		0.54	0.95	0.03	0.9	0.59	0.52	0.74	0.41	0.79	0.41	0.41	0.86	-0.65	-0.4	0.72	0.63	0.88	-0.3	0.64	0.18	0.63	0.22	-0.62	-0.39
Net Debt	0.7	0.54		0.48	-0.27	0.75	0.19	0.62	0.21	0.35	0.64	-0.18	-0.18	0.74	-0.81	-0.67	0.89	0.74	0.7	0.18	0.58	0.06	0.69	0.3	-0.54	-0.6
Retained Earnings	0.93	0.95	0.48		-0.03	0.9	0.76	0.44	0.77	0.54	0.86	0.34	0.34	0.74	-0.61	-0.22	0.7	0.48	0.9	-0.49	0.56	0.37	0.52	0.32	-0.46	-0.23
Accounts Payable	-0.05	0.03	-0.27	-0.03		-0.09	0.23	-0.31	0.27	-0.11	0.04	0.44	0.44	-0.3	0.4	0.27	-0.46	-0.45	0.02	-0.21	-0.36	0.28	-0.13	0.21	0.43	0.27
Total Liab	0.99	0.9	0.75	0.9	-0.09		0.6	0.64	0.71	0.49	0.93	0.16	0.16	0.85	-0.8	-0.54	0.83	0.7	0.96	-0.23	0.69	0.22	0.75	0.24	-0.55	-0.49
Total Current Assets	0.61	0.59	0.19	0.76	0.23	0.6		0.15	0.58	0.75	0.75	0.19	0.19	0.21	-0.31	0.32	0.34	-0.1	0.69	-0.71	0.11	0.68	0.02	0.46	0.1	0.32
Short Term Debt	0.62	0.52	0.62	0.44	-0.31	0.64	0.15		0.17	0.52	0.5	-0.05	-0.05	0.66	-0.9	-0.6	0.63	0.67	0.52	0.27	0.7	-0.45	0.64	-0.42	-0.58	-0.38
Net Receivables	0.73	0.74	0.21	0.77	0.27	0.71	0.58	0.17		0.12	0.79	0.52	0.52	0.52	-0.28	-0.28	0.32	0.32	0.76	-0.33	0.33	0.35	0.58	0.22	-0.11	-0.38
Short Term Investments	0.47	0.41	0.35	0.54	-0.11	0.49	0.75	0.52	0.12		0.55	-0.02	-0.02	0.18	-0.61	0.23	0.44	0.0	0.51	-0.42	0.21	0.28	0.01	0.09	-0.03	0.37
Long Term Debt	0.91	0.79	0.64	0.86	0.04	0.93	0.75	0.5	0.79	0.55		0.17	0.17	0.65	-0.68	-0.35	0.7	0.47	0.96	-0.29	0.53	0.39	0.64	0.35	-0.24	-0.34
Capital Stock	0.24	0.41	-0.18	0.34	0.44	0.16	0.19	-0.05	0.52	-0.02	0.17		1.0	0.12	0.03	0.0	-0.13	-0.02	0.24	-0.31	-0.02	-0.01	0.21	-0.02	0.05	-0.01
Common Stock	0.24	0.41	-0.18	0.34	0.44	0.16	0.19	-0.05	0.52	-0.02	0.17	1.0		0.12	0.03	0.0	-0.13	-0.02	0.24	-0.31	-0.02	-0.01	0.21	-0.02	0.05	-0.01
Property Plant Equipment	0.87	0.86	0.74	0.74	-0.3	0.85	0.21	0.66	0.52	0.18	0.65	0.12	0.12		-0.77	-0.73	0.87	0.93	0.76	0.1	0.81	-0.13	0.79	0.07	-0.86	-0.72
Current Deferred Revenue	-0.77	-0.65	-0.81	-0.61	0.4	-0.8	-0.31	-0.9	-0.28	-0.61	-0.68	0.03	0.03	-0.77		0.6	-0.84	-0.76	-0.72	-0.13	-0.7	0.19	-0.7	0.15	0.6	0.47
Net Tangible Assets	-0.51	-0.4	-0.67	-0.22	0.27	-0.54	0.32	-0.6	-0.28	0.23	-0.35	0.0	0.0	-0.73	0.6		-0.56	-0.89	-0.42	-0.54	-0.64	0.45	-0.9	0.23	0.62	0.93
Total Permanent Equity	0.82	0.72	0.89	0.7	-0.46	0.83	0.34	0.63	0.32	0.44	0.7	-0.13	-0.13	0.87	-0.84	-0.56		0.8	0.77	0.01	0.75	0.07	0.64	0.31	-0.71	-0.53
Good Will	0.69	0.63	0.74	0.48	-0.45	0.7	-0.1	0.67	0.32	0.0	0.47	-0.02	-0.02	0.93	-0.76	-0.89	0.8		0.58	0.35	0.76	-0.34	0.83	-0.13	-0.85	-0.86
Long Term Debt Total	0.96	0.88	0.7	0.9	0.02	0.96	0.69	0.52	0.76	0.51	0.96	0.24	0.24	0.76	-0.72	-0.42	0.77	0.58		-0.34	0.57	0.36	0.69	0.34	-0.37	-0.41
Capital Surpluse	-0.25	-0.3	0.18	-0.49	-0.21	-0.23	-0.71	0.27	-0.33	-0.42	-0.29	-0.31	-0.31	0.1	-0.13	-0.54	0.01	0.35	-0.34		0.23	-0.74	0.3	-0.47	-0.22	-0.5
Deferred Long Term Liab	0.69	0.64	0.58	0.56	-0.36	0.69	0.11	0.7	0.33	0.21	0.53	-0.02	-0.02	0.81	-0.7	-0.64	0.75	0.76	0.57	0.23		-0.38	0.71	-0.08	-0.76	-0.55
Long Term Investments	0.21	0.18	0.06	0.37	0.28	0.22	0.68	-0.45	0.35	0.28	0.39	-0.01	-0.01	-0.13	0.19	0.45	0.07	-0.34	0.36	-0.74	-0.38		-0.25	0.78	0.38	0.31
Intangible Assets	0.73	0.63	0.69	0.52	-0.13	0.75	0.02	0.64	0.58	0.01	0.64	0.21	0.21	0.79	-0.7	-0.9	0.64	0.83	0.69	0.3	0.71	-0.25		-0.11	-0.53	-0.84
Short Long Term Debt	0.24	0.22	0.3	0.32	0.21	0.24	0.46	-0.42	0.22	0.09	0.35	-0.02	-0.02	0.07	0.15	0.23	0.31	-0.13	0.34	-0.47	-0.08	0.78	-0.11		0.09	0.1
Net Invested Capital	-0.58	-0.62	-0.54	-0.46	0.43	-0.55	0.1	-0.58	-0.11	-0.03	-0.24	0.05	0.05	-0.86	0.6	0.62	-0.71	-0.85	-0.37	-0.22	-0.76	0.38	-0.53	0.09		0.59
Net Working Capital	-0.48	-0.39	-0.6	-0.23	0.27	-0.49	0.32	-0.38	-0.38	0.37	-0.34	-0.01	-0.01	-0.72	0.47	0.93	-0.53	-0.86	-0.41	-0.5	-0.55	0.31	-0.84	0.1	0.59

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Gilead Sciences

Ebitda Over Time

Gilead Ebitda

Ebitda

4.93 Billion

At present, Gilead Sciences' EBITDA is projected to increase significantly based on the last few years of reporting.

According to the company disclosure, Gilead Sciences reported earnings before interest,tax, depreciation and amortization of 7.61 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 95.07% lower than that of the firm.

Gilead EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.

Gilead Sciences is currently under evaluation in ebitda category among related companies.

Gilead Sciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gilead Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gilead Sciences' managers, analysts, and investors.

Environment Score

Governance Score

Social Score

Gilead Sciences Institutional Holders

Institutional Holdings refers to the ownership stake in Gilead Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gilead Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gilead Sciences' value.

		Shares
Norges Bank	2023-12-31	16.1 M
Bank Of New York Mellon Corp	2023-12-31	15.5 M
Northern Trust Corp	2023-12-31	14 M
Legal & General Group Plc	2023-12-31	12.5 M
Parnassus Investments Llc	2023-12-31	12 M
Amvescap Plc.	2023-12-31	11.6 M
Nuveen Asset Management, Llc	2023-12-31	11.5 M
Royal Bank Of Canada	2023-12-31	10.6 M
Amundi	2023-12-31	10.5 M
Blackrock Inc	2023-12-31	122.8 M
Vanguard Group Inc	2023-12-31	111.8 M

Gilead Fundamentals

	Return On Equity	0.26
	Return On Asset	0.0978
	Profit Margin	0.21 %
	Operating Margin	0.42 %
	Current Valuation	100.73 B
	Shares Outstanding	1.25 B
	Shares Owned By Institutions	88.27 %
	Number Of Shares Shorted	22.57 M
	Price To Earning	359.42 X
	Price To Book	3.72 X
	Price To Sales	3.13 X
	Revenue	27.12 B
	Gross Profit	21.62 B
	EBITDA	7.61 B
	Net Income	5.61 B
	Cash And Equivalents	6.14 B
	Cash Per Share	4.90 X
	Total Debt	24.99 B
	Debt To Equity	1.30 %
	Current Ratio	1.43 X
	Book Value Per Share	18.32 X
	Cash Flow From Operations	8.01 B
	Short Ratio	3.06 X
	Earnings Per Share	4.50 X
	Price To Earnings To Growth	0.42 X
	Target Price	78.7
	Number Of Employees	18 K
	Beta	0.2
	Market Capitalization	83.58 B
	Total Asset	62.12 B
	Retained Earnings	16.3 B
	Working Capital	4.8 B
	Current Asset	1.18 B
	Current Liabilities	104.89 M
	Annual Yield	0.05 %
	Five Year Return	3.76 %
	Net Asset	62.12 B
	Last Dividend Paid	3.0

About Gilead Sciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

How To Invest In Gilead

Details

Is Gilead Stock a good investment?

Details

What is Gilead Sciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Gilead Sciences Piotroski F Score and Gilead Sciences Altman Z Score analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume

Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.13)

Dividend Share

Earnings Share

4.5

Revenue Per Share

21.728

Quarterly Revenue Growth

(0.04)

The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gilead Sciences Stock EBITDA

Gilead Sciences Company EBITDA Analysis

EBITDA

Revenue

-

Basic Expenses

Current Gilead Sciences EBITDA

Gilead EBITDA Driver Correlations

Gilead Ebitda

Ebitda

4.93 Billion

Gilead EBITDA Peer Comparison

Gilead Sciences ESG Sustainability

Gilead Sciences Institutional Holders

Gilead Fundamentals

About Gilead Sciences Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Gilead Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY